# Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

> **NCT06212648** · PHASE2 · COMPLETED · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 253 (actual)

## Conditions studied

- Hypertension
- Essential Hypertension

## Interventions

- **DRUG:** SPC1001 High
- **DRUG:** SPC1001 Mid1
- **DRUG:** SPC1001 Mid2
- **DRUG:** SPC1001 Low
- **DRUG:** SPC3001
- **DRUG:** SPC4001
- **DRUG:** SPC4002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06212648
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-25
- **Primary completion:** 2022-11-27
- **Final completion:** 2023-01-27
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06212648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06212648, "Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06212648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*